Earendil Labs struck an exclusive deal to access WuXi XDC’s WuXiTecan‑2 payload‑linker technology for next‑generation antibody‑drug conjugates, a transaction valued at up to $885 million in upfront and milestone payments plus tiered royalties. WuXi XDC will also provide CRDMO services to support ADC component manufacturing. Earendil, an AI‑driven biologics developer with an emphasis on bispecifics and multispecific ADCs, said the license would accelerate its ADC pipeline. WuXi XDC positioned the agreement as validation of its linker‑payload platform and contract capabilities. Both companies highlighted the deal’s potential to speed development timelines and improve payload safety/efficacy profiles. The pact underscores continued strategic interest in combining AI design and established linker technologies to de‑risk complex biologic modalities on expedited timelines.